Project Details
Description
Primary Objective:
- To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
- To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
- To continue to assess the safety and tolerability throughout the study.
- To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
Secondary Objectives:
- To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation.
- To continue to assess the safety and tolerability throughout the study.
Layman's description
Duration per participant was up to 28 weeks.
| Status | Finished |
|---|---|
| Effective start/end date | 22/08/19 → 6/10/21 |
Collaborative partners
- Sanofi (lead)
- Dubai Health Authority
- Abu Dhabi Health Services Company
- Regeneron Pharmaceuticals, Inc.
Keywords
- Skin Diseases
- Genetic Skin Diseases
- Inborn Genetic Diseases
- Eczematous Skin Diseases
- Immediate Hypersensitivity
- Hypersensitivity
- Immune System Diseases
- Atopic Dermatitis
- Dermatitis
- Eczema
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.